A comparison of remission rate at 8 weeks between combination therapy of Ustekinumab and Budesonide and monotherapy of Ustekinumab in moderate to severe Japanese Crohn's disease; A phase III, single-center, double blind, randomized control trial.
Phase of Trial: Phase III
Latest Information Update: 26 Jul 2018
At a glance
- Drugs Ustekinumab (Primary) ; Budesonide
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms BUUST study
- 20 Jul 2018 Status changed from not yet recruiting to recruiting.
- 21 Feb 2018 New trial record